Pluristem Therapeutics to Sponsor the World Conference on Regenerative Medicine

NEW YORK--(Business Wire)--
Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT), a bio-therapeutics company
dedicated to the commercialization of unrelated donor-patient (allogeneic) cell
therapy products for a variety of disorders, announced today that it will be
sponsoring the World Conference on Regenerative Medicine to be held on October
29-31, 2009 in Leipzig, Germany. The conference, which will be organized by the
Fraunhofer Institute for Cell Therapy and Immunology, will provide a platform
for the exchange of information on stem cells, tissue engineering, technology
development such as bioreactors, immunology signaling and regulatory topics.

"Pluristem is honored to sponsor the World Conference of Regenerative Medicine",
stated Zami Aberman, Chairman, President and CEO of Pluristem. "This conference
presents the current science on the threshold of cell therapy, and we at
Pluristem believe that cell therapy will give patients a better chance", he
added.

Prof. Dr. Frank Emmrich, Director of the Institute for Clinical Immunology and
Transfusion Medicine, University of Leipzig, Germany,stated, "We are pleased
that Pluristem continues to sponsor the World Conference on Regenerative
Medicine. Pluristem`s involvement reflects its continuous commitment to the
field of bio-therapy as well as the Company`s acknowledgment of the significance
of the German scientific institutions in Leipzig."

http://www.wcrm-leipzig.com/index.php

About Fraunhofer Institute for Immunology and Cell Therapy

The objective of the Fraunhofer Institute for Immunology and Cell Therapy (IZI)
is to find solutions to specific problems at the interfaces between medicine,
life sciences and engineering for partners active in medicine-related industries
and businesses. The Institute`s core competencies are found in regenerative
medicine, or more precisely in cell-therapeutic methods of regenerating
non-functioning tissue and organs through to biological substitution with tissue
cultivated in vitro (tissue engineering). In order for the living organism to
accept these tissues without difficulty, it is necessary to study cellular and
immunological defense and control mechanisms and take these into account during
the process product development. These core competencies entail a multiplicity
of tasks to be solved by new products and processes.

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the
commercialization of unrelated donor-patient (allogeneic) cell therapy products
for the treatment of several severe degenerative, ischemic and autoimmune
disorders. The Company is developing a pipeline of products, stored
ready-to-use, that are derived from human placenta, a non-controversial,
non-embryonic, adult stem cell source.

These placental adherent stromal cells (ASCs) are expanded in the Company's
proprietary PluriXTM 3D bioreactor, which imitates the natural 3D
microenvironment of these cells and does not require supplemental growth factors
or other exogenous materials. Pluristem believes that the resultant PLX
(PLacental eXpanded) cells` efficacy may be related to the secretion of
cytokines or other potent immune modulators. Furthermore, PLX cells are immune
privileged and possess immunomodulatory properties, thus protecting the
recipient from immunological reactions that often accompany transplantations.

Pluristem's first product in development, PLX-PAD, is intended to improve the
quality of life of millions of people suffering from peripheral artery disease
(PAD). The Company's products in development also include PLX-IBD, targeting
Inflammatory Bowel Disease (IBD); PLX-MS, targeting Multiple Sclerosis; PLX-BMT,
targeting the global shortfall of matched tissue for bone marrow transplantation
(BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained
in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.

Pluristem has offices in the USA with research and manufacturing facilities in
Israel.

See our product animation on YouTube: Animation

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995 and federal securities laws. For example, when we say that we believe that
cell therapy will give patients a better chance, we are using forward-looking
statements. These forward-looking statements are based on the current
expectations of the management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. The following factors,
among others, could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology and market
requirements; our technology may not be validated as we progress further and our
methods may not be accepted by the scientific community; we may be unable to
retain or attract key employees whose knowledge is essential to the development
of our products; unforeseen scientific difficulties may develop with our
process; results in the laboratory may not translate to equally good results in
real surgical settings; our patents may not be sufficient; our products may harm
recipients; changes in legislation; inability to timely develop and introduce
new technologies, products and applications; loss of market share and pressure
on pricing resulting from competition, which could cause the actual results or
performance of Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Pluristem
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more detailed
description of the risk and uncertainties affecting Pluristem, reference is made
to Pluristem's reports filed from time to time with the Securities and Exchange
Commission.

For more information visit our website at www.pluristem.com, the content of
which is not part of this press release.

Pluristem Therapeutics Inc.
William Prather RPh, MD
Sr. VP Corporate Development
+1-303-883-4954
William.PratherMD@pluristem.com

Copyright Business Wire 2009